WuXi AppTec (2359) Announces Disposal of WuXi Clinical and WuXi MedKey to Hillhouse

Bulletin Express

Oct 26

On October 24, 2025, WuXi AppTec Co., Ltd. (Stock Code: 2359) announced that its wholly-owned subsidiary, WuXi AppTec (Shanghai) Co., Ltd., entered into a sale and purchase agreement with Hillhouse Investment Management to sell all shares of WuXi Clinical Development Services (Shanghai) Co., Ltd. and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. The transaction’s objective is to strengthen WuXi AppTec’s core CRDMO services, involving drug discovery, laboratory testing, process development, and manufacturing.

According to the announcement, WuXi Clinical and WuXi MedKey generated combined revenue of approximately RMB1.16 billion from January to September 2025, accounting for about 3.5% of WuXi AppTec’s unaudited revenue during that period. Their combined net profit was approximately RMB0.09 billion, representing about 0.7% of the company’s unaudited net profit for the same interval. The transaction does not constitute a connected or notifiable transaction under relevant listing rules, and completion is subject to conditions precedent and necessary regulatory approvals. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1183599139"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183599139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183599139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-26 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183599139","market":"hk","top_or_hot":-1,"title":"WuXi AppTec (2359) Announces Disposal of WuXi Clinical and WuXi MedKey to Hillhouse","media":"Bulletin Express","content":"<p>On October 24, 2025, WuXi AppTec Co., Ltd. (Stock Code: 2359) announced that its wholly-owned subsidiary, WuXi AppTec (Shanghai) Co., Ltd., entered into a sale and purchase agreement with Hillhouse Investment Management to sell all shares of WuXi Clinical Development Services (Shanghai) Co., Ltd. and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. The transaction’s objective is to strengthen WuXi AppTec’s core CRDMO services, involving drug discovery, laboratory testing, process development, and manufacturing.</p>\n<p>According to the announcement, WuXi Clinical and WuXi MedKey generated combined revenue of approximately RMB1.16 billion from January to September 2025, accounting for about 3.5% of WuXi AppTec’s unaudited revenue during that period. Their combined net profit was approximately RMB0.09 billion, representing about 0.7% of the company’s unaudited net profit for the same interval. The transaction does not constitute a connected or notifiable transaction under relevant listing rules, and completion is subject to conditions precedent and necessary regulatory approvals. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi AppTec (2359) Announces Disposal of WuXi Clinical and WuXi MedKey to Hillhouse</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi AppTec (2359) Announces Disposal of WuXi Clinical and WuXi MedKey to Hillhouse\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-26 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On October 24, 2025, WuXi AppTec Co., Ltd. (Stock Code: 2359) announced that its wholly-owned subsidiary, WuXi AppTec (Shanghai) Co., Ltd., entered into a sale and purchase agreement with Hillhouse Investment Management to sell all shares of WuXi Clinical Development Services (Shanghai) Co., Ltd. and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. The transaction’s objective is to strengthen WuXi AppTec’s core CRDMO services, involving drug discovery, laboratory testing, process development, and manufacturing.</p>\n<p>According to the announcement, WuXi Clinical and WuXi MedKey generated combined revenue of approximately RMB1.16 billion from January to September 2025, accounting for about 3.5% of WuXi AppTec’s unaudited revenue during that period. Their combined net profit was approximately RMB0.09 billion, representing about 0.7% of the company’s unaudited net profit for the same interval. The transaction does not constitute a connected or notifiable transaction under relevant listing rules, and completion is subject to conditions precedent and necessary regulatory approvals. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"","article_id":"1183599139","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183599139","pubTimestamp":1761475510,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On October 24, 2025, WuXi AppTec Co., Ltd. (Stock Code: 2359) announced that its wholly-owned subsidiary, WuXi AppTec (Shanghai) Co., Ltd., entered into a sale and purchase agreement with Hillhouse...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02359":"药明康德"},"translate_title":"药明康德(2359)公布向高瓴出售WuXi Clinical及WuXi MedKey","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"On October 24, 2025, WuXi AppTec Co., Ltd. (Stock Code: 2359) announced that its wholly-owned subsidiary, WuXi AppTec (Shanghai) Co., Ltd., entered into a sale and purchase agreement with Hillhouse Investment Management to sell all shares of WuXi Clinical Development Services (Shanghai) Co., Ltd. and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. The transaction’s objective is to strengthen WuXi AppTec’s core CRDMO services, involving drug discovery, laboratory testing, process development, and manufacturing.\nAccording to the announcement, WuXi Clinical and WuXi MedKey generated combined revenue of approximately RMB1.16 billion from January to September 2025, accounting for about 3.5% of WuXi AppTec’s unaudited revenue during that period. Their combined net profit was approximately RMB0.09 billion, representing about 0.7% of the company’s unaudited net profit for the same interval. The transaction does not constitute a connected or notifiable transaction under relevant listing rules, and completion is subject to conditions precedent and necessary regulatory approvals. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}